Dynavax Technologies Corporation | Date: 2016-09-13
The present invention relates to immunization of hypo-responsive groups of individuals. In particular, the present invention provides methods and compositions for eliciting a potent immune response to hepatitis B virus in individuals in need thereof.
Dynavax Technologies Corporation | Date: 2016-08-09
The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.
Coffman R.L.,Dynavax Technologies Corporation |
Sher A.,National Institute of Allergy and Infectious Diseases |
Seder R.A.,National Institute of Allergy and Infectious Diseases
Immunity | Year: 2010
Adjuvants enhance immunity to vaccines and experimental antigens by a variety of mechanisms. In the past decade, many receptors and signaling pathways in the innate immune system have been defined and these innate responses strongly influence the adaptive immune response. The focus of this review is to delineate the innate mechanisms by which adjuvants mediate their effects. We highlight how adjuvants can be used to influence the magnitude and alter the quality of the adaptive response in order to provide maximum protection against specific pathogens. Despite the impressive success of currently approved adjuvants for generating immunity to viral and bacterial infections, there remains a need for improved adjuvants that enhance protective antibody responses, especially in populations that respond poorly to current vaccines. However, the larger challenge is to develop vaccines that generate strong T cell immunity with purified or recombinant vaccine antigens. © 2010 Elsevier Inc.
Dynavax Technologies Corporation | Date: 2015-02-03
The application relates to the use of immunoregulatory polynucleotides and/or immunoregulatory compounds in combination with other therapeutic agents. The application further relates to immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence. It also relates to the administration of the immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence to regulate an immune response.
Dynavax Technologies Corporation | Date: 2016-01-22
The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.
Dynavax Technologies Corporation | Date: 2014-07-18
The invention provides methods for treating asthma by using multiple rounds of administration of ISS over a period of time to confer long term disease modification.
Dynavax Technologies Corporation | Date: 2016-05-23
The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
Dynavax Technologies Corporation | Date: 2015-04-22
The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.
Dynavax Technologies Corporation | Date: 2015-04-23
Provided herein are human Toll-like receptor 8 (TLR8)-expressing transgenic animals and methods of use thereof.
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase II | Award Amount: 530.77K | Year: 2016
DESCRIPTION provided by applicant Autoimmune diseases like rheumatoid arthritis RA develop when the immune response targets self antigens leading to inflammation and tissue destruction There is now considerable evidence that recognition of self nucleic acids through toll like receptors TLRs can contribute significantly to sterile inflammation and autoimmunity with the clearest example being the role played by TLR and TLR in the pathogenesis of systemic lupus erythematosus SLE Similarly TLR a potent stimulator of inflammatory cytokines such as IL and TNF has a strong association with RA and other autoimmune indications However the lack of useful animal models a consequence of the different ligand specificity of human TLR and its rodent orthologs has proven to be a major limitation in the study of TLR function and the identification of possible therapeutics We have developed new tools including in vivo animal models that have allowed us to better understand the biology of TLR in autoimmunity and specifically for a role of TLR signaling in RA We propose to use these tools to identify a lead small molecule antagonist for developing a therapeutic for TLR mediated autoimmunity The key objective of this Phase II proposal is to identify lead small molecule antagonists of human TLR from a set of candidate hits that we have identified through high throughput screening with funding from a Phase I SBIR The principal activities will include Advancing hits and identifying lead compounds with specific and improved huTLR antagonist activity through a process of iterative computer aided drug design with structure based modeling and cell based activity Determining the activity of the lead candidates in TLR dependent RA mouse model Conducting preliminary toxicology of lead compounds to support IND enabling studies If successful we anticipate obtaining a small number of lead small molecule candidates that inhibit TLR and have sufficient attributes e g potency to move into IND enabling studies PUBLIC HEALTH RELEVANCE There are drugs that have proven clinically beneficial for the treatment of rheumatoid arthritis RA but these treatments are not effective in all patients and are not without serious side effects This work attempts to develop a drug against a new target human Toll Like Receptor that has been demonstrated to be involved with a variety of autoimmune diseases including RA Our initial efforts have been successful in identifying potential candidates that inhibit this target and the work in this proposal will optimize those candidates and test for anti rheumatic activity in animal models to allow us to move into the clinic